Contact this trialFirst, we need to learn more about you.
Anti-metabolites
Mirvetuximab Soravtansine + Gemcitabine Hydrochloride for Ovarian, Breast, Fallopian Tube, Peritoneal, and Uterine Cancer
Recruiting1 awardPhase 1
Upland, California
This trial is testing the side effects and best dose of two drugs, mirvetuximab soravtansine and gemcitabine hydrochloride, in treating patients with cancer that has come back. Mirvetuximab soravtansine is a monoclonal antibody linked to a chemotherapy drug, and gemcitabine hydrochloride is a chemotherapy drug.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.